BIT's 18th Annual Congress of International Drug Discovery Science and Technology (IDDST-2023)
Scientific Program

Day 1 | Day 2 | Day 3

 

Keynote Forum

Day 1: Morning, July. 12, 2023

Moderator

Dr. Mattias von Herrath, Vice President/Head NovoNordisk; Professor/Director of the Diabetes Center, La Jolla Institute, USA

Time

Speeches and Speakers

09:00-09:05

Chair's Introduction

09:05-09:30

Title: Tankyraseinhibitors: Evidence for Therapeutic Potential in Immuno-oncology

Dr. Luc Van Hijfte, SVP Medicinal Chemistry, Symeres, the Netherlands

09:30-09:55

Title: TBD

Dr. Mattias von Herrath, Vice President/Head NovoNordisk; Professor/Director of the Diabetes Center, La Jolla Institute, USA

09:55-10:20

Title: Nanoparticles for Gene and Drug Delivery: Applying Light Scattering to Screening and Characterization

Dr. Daniel Some, Principal Scientist, Wyatt Technology Corporation, USA

10:20-10:45

Title: The Role of ABC Membrane Transporters in Personalized Diagnostics and Drug Treatment

Dr. Balazs Sarkadi, Professor, Semmelweis University, Hungary

10:45-11:10

Title: Next Generation T Cell Therapy Products Partnering with Pfizer – Introduction to Emerging Science & Innovation

Dr. Uwe Schoenbeck, Senior Vice President & Chief Scientific Officer, Worldwide R & D, Pfizer, USA

11:10-11:35

Title: New Innovative Ways to Enhance Treatment Targeting and Individualization: The Complementary Use of Predicting Modeling and Machine Learning in the Field of Diabetes and Metabolic Disorders

Dr. Zsolt Bosnyak, Chief Medical Officer, Richter Gedeon Nyrt., France

 

Session 211: Pharmacogenetics, Pharmacogenomics and Precision Medicine 

Day 1: Afternoon, July. 12, 2023

Chair

Dr. Godefridus J Peters, Professor in Pharmacology of Cytostatics, Amsterdam University Medical Centers, the Netherlands; Professor in Biochemistry, Medical University of Gdansk, Poland

Time

Speeches and Speakers

13:30-13:35

Chair's Introduction

13:35-14:05

Keynote Speech

Title: Personalized and Precision Medicine (PPM) as a Unique Healthcare Model to be Set Up via Translational Applications and Upgraded Business Modeling to Secure the Human Healthcare, Wellness and Biosafety

Dr. Sergey Suchkov, Professor, Director, Center for Personalized Medicine, I.M. Sechenov First Moscow State Medical University, Russia

14:05-14:30

Title: The Role of Pharmacogenetics and Drug Discovery

Dr. Godefridus J Peters, Professor in Pharmacology of Cytostatics, Amsterdam University Medical Centers, the Netherlands; Professor in Biochemistry, Medical University of Gdansk, Poland

14:30-14:55

Title: Testing Complex Activity Profiles of Human Immune Cell using a Highly Standardised Bed-side Whole Blood Culture Model

Dr. Manfred Schmolz, CEO/CSO, HOT Screen GmbH, Germany

14:55-15:20

Speech Opportunity Available
Abstract and Biography: Submit Here

15:20-15:30

Coffee Break

  15:30-15:55

Title: Optimized and Fully Characterized Drugs Together with Disease Understanding: De-risking Clinical Development

Dr. Peter Staller, Head of Functional Genomics Research,  Nuvisan Pharma Services Group, Germany

  15:55-16:20

Title: Precision Medicine at the Interface of Translational Research and Systems Medicine

Dr. Kristel Van Steen, Professor, University of Liege/KU Leuven, Belgium

  16:20-16:45

Title: Personalized Treatment of Chronic Wounds

Dr. Barbara Wolff-Winiski, Co-CEO and CSO, AKRIBES Biomedical GmbH, Austria

  16:45-17:10

Speech Opportunity Available
Abstract and Biography: Submit Here

 

Session 221: Innovative Drug Discovery Technology

Day 1: Afternoon, July. 12, 2023

Chair

Dr. Alexey RAK, Director of Bio Structure and Biophysics, Sanofi R&D, France

  Co-chair
 Dr. Barry Morgan, CSO, Hitgen Ltd., USA

Time

Speeches and Speakers

13:30-13:35

Chair's Introduction

13:35-13:55

Title: TBD

Dr. Alexey RAK, Director of Bio Structure and Biophysics, Sanofi R&D, France

13:55-14:15

Speech Opportunity Available
Abstract and Biography: Submit Here

14:15-14:35

Title: Cold Chain Options for Cryopreservation and Transport of Natural and Bioengineered Tissues

Dr. Kelvin Brockbank, Chief Executive Officer, Tissue Testing Technologies LLC, USA

14:35-14:55

Title: Assays, Biophysics and Structural Biology towards Drugs with Innovative Inhibition Mode

Dr. Lars Neumann, Director Assays, Biophysics & Screening, Proteros biostructures GmbH, Germany

  14:55-15:15

Title: The Importance of Physicochemical Properties for the Bioavailability of Pharmaceutical Compounds

Dr. Rebeca Ruiz, Global Analytical Services Manager, Sirius Analytical Instruments Ltd, UK

15:15-15:30

Coffee Break

15:30-15:50

Title: Demystifying DEL: DNA Encoded Library Technology is not (that) Complicated!

Dr. Barry Morgan, CSO, Hitgen Ltd., USA

15:50-16:10

Title: Application of an Antibiotic-free Selection System and Use of an AI-assisted Process Optimization Approach

Dr. Marinka Gudelj-Wyletal, Scientist, Process Science & Upstream Development, Boehringer Ingelheim RCV GmbH & Co KG, Austria

16:10-16:30

Title: Machine Learning Enabled Epitope Selective Antibody Discovery: Epitopes are the Foundation of Efficacy

Dr. Isaac Bright, Chief Executive Officer, RubrYc Therapeutics, Inc, USA

  16:30-16:50

Title: The Strep-tag Technology - The Superior Tag System for the Entire Protein Production Workflow

Dr. Dennis Karthaus, Director Protein Products and Assays, IBA GmbH, Germany

  16:50-17:10

Title: Accelerated Protein Development with Integrated Cell Free Expression, Purification, and Bioconjugation, Evaluated with Time-gated Raman

Dr. Marco G Casteleijn, Senior Scientist, VTT Technical Research Centre of Finland Ltd., Finland

 

Session 311: Cancer Drug Targets  

Day 1: Afternoon, July. 12, 2023

Chair

Dr. Laszlo Takacs, Member of the Hungarian Academy of Sciences, Laboratory of Monoclonal Antibody Proteomics, Department of Human Genetics, University of Debrecen, Hungary

Time

Speeches and Speakers

13:30-13:35

Chair's Introduction

13:35-14:00

Title: Epitome Level Screening Delivers New Drug Targets beyond Proteins

Dr. Laszlo Takacs, Member of the Hungarian Academy of Sciences, Laboratory of Monoclonal Antibody Proteomics, Department of Human Genetics, University of Debrecen, Hungary

14:00-14:25

Speech Opportunity Available
Abstract and Biography: Submit Here

14:25-14:50

Title: Reshaping Immune Lung Populations to Inhibit Lung Cancer and Fibrosis by Activation of Purinergic Receptor P2RX7

Dr. Valerie Vouret-Craviari, Research Director, DR2 CNRS, France

14:50-15:15

Title: Targeting Human G-quadruplex Formed by Telomeric DNA and C9orf72 Hexanucleotide Repeats

Dr. Guang Zhu, Professor, The Hong Kong Univ. of Sci. and Tech., Hong Kong, China

15:15-15:30

Coffee Break

15:30-15:55

Title: Breaking Steroid Resistance by Targeted Compounds in Pediatric T-cell Acute Lymphoblastic Leukemia

Dr. Jules P. P. Meijerink, Principal Investigator, Princess Maxima Center for Paediatric Oncology, the Netherlands

15:55-16:20

Title: Arsenic Trioxide is Effective in Treating T-ALL and Synergistic Effect when Combined with Ruxolitinib

Dr. Sin Chun Fung, Assistant Professor, University of Hong Kong, Hong Kong, China

16:20-16:45

Title: The Role of TGFb-regulated microRNAs and LIN28B in Pancreatic Adenocarcinoma Progressions

Dr. Leandro Castellano, Honorary Senior Lecturer, University of Sussex, UK

16:45-17:10

Title: Small But Mighty; The Cutting-Edge Role of PD-L1 Small Molecule Inhibitors in Cancer

Dr. Hend M El Tayebi, Associate Professor, German University in Cairo, Egypt

 

Session 321: Open Innovation in Drug Discovery

Day 1: Afternoon, July. 12, 2023

Chair

Dr. Florian Montel, Head of opnMe.com & CNS Project Leader, Boehringer Ingelheim, Germany

Time

Speeches and Speakers

13:30-13:35

Chair's Introduction

13:35-14:00

Title: TBD

Dr. Yoshinori Ikeura, CEO, Axcelead Drug Discovery Partners, Inc., Japan

14:00-14:25

Title: opnMe.com, The Boehringer Ingelheim Open Innovation Portal to Reach out to New Biology: 2 years of Experience and Perspectives for the Next 3 Years

Dr. Florian Montel, Head of opnMe.com & CNS Project Leader, Boehringer Ingelheim, Germany

14:25-14:50

Speech Opportunity Available
Abstract and Biography: Submit Here

14:50-15:15

Title: MAPK Cascade as a Drug Target for the Prevention of Adhesive Disease

Dr. Mikhail Shurygin, Research Director, Pharmasyntez, Russia

15:15-15:30

Coffee Break

  15:30-15:55

Speech Opportunity Available
Abstract and Biography: Submit Here

  15:55-16:20

Speech Opportunity Available
Abstract and Biography: Submit Here

  16:20-16:45

Title: A Quantum-Inspired Approach to De-Novo Drug Design

Ms. Ellen Devereux, Digital Annealer Consultant, Fujitsu, UK

 

Session 411: Cancers/Tumors

Day 1: Afternoon, July. 12, 2023

Chair

Dr. Luana Pesco Koplowitz, Chief Medical & Scientific Officer, DUCK FLATS Pharma, USA

 Co-Chair   Dr. Hidemitsu Nakagawa, President, Nozaki Tokushukai Hospital, Japan

Time

Speeches and Speakers

13:30-13:35

Chair's Introduction

13:35-13:55

Title: Radioactive Tracer Technology Applied to Clinical Pharmacology -a Historical Review based on Personal Experiences in Japan with Future Perspectives

Dr. Yasuhito Sasaki, Director, Research Center for Radiation Oncology, Shonankamakura General HospitalAffiliated Clinical Research Center; Visiting Professor, Graduate School of Yokohama City University, Japan

13:55-14:15

Title: Chemotherapeutic Treatment of Infants with Cancer: Challenges and Opportunities

Dr. Luana Pesco Koplowitz, Chief Medical & Scientific Officer, DUCK FLATS Pharma, USA

14:15-14:35

Title: Melatonin as an Antioxidant and Anti-cancer Agent: Directing it to the Mitochondria

Dr. Russel J Reiter, Professor, UT Heath, USA

  14:35-14:55

Title: Correlation of in Situ Oxazolidine Formation with Highly Synergistic Cytoxicity and DNA Cross-Linking in Cancer Cells from Combination of Doxorubicin and Formaldehyde

Dr. Ben Barthel, Scientist, University of Colorado, USA

  14:55-15:15

Title: OXC-101 (TH1579): A Novel Way to Treat Acute Myeloid Leukemia by Inducing Mitotic Arrest, ROS and Oxidative Damage

Dr. Ulrika Warpman Berglund, CEO, Oxcia AB, Sweden

15:15-15:30

Coffee Break

15:30-15:50

Title: Intrathecal Sodium Butyrate for Malignant Brain Tumors and Lleptomeningeal Metastasis of Malignant Tumors-experimental Research and Clinical Trial

Dr. Hidemitsu Nakagawa, President, Nozaki Tokushukai Hospital, Japan

15:50-16:10

Title: TBD

Dr. Robert Huigens, Assistant Professor, University of Florida, USA

16:10-16:30

Title:  HA Conjugated Drugs in Cancer Therapy

Dr. James Neil Hunter, International Healthcare Activities Director, Holy Stone Biotech Co Ltd, UK

16:30-16:50

Title: Methylglyoxal: A Non Toxic and Potent Therapeutic Agent for Triple Negative Breast Cancer

Dr. Manju Ray, Professor, Department of Biophysics, Bose Institute, India 

  16:50-17:10

Title:  Aurora Kinase A Inhibitor (VX 680) Inhibits Cell Migration, Invasion, Proliferation and Viability and Promotes Cell Apoptosis in Human Prostate Cancer (PC3) Cells

Dr. Ahmad Al-Azayzih, Assistant Professor, United Arab Emirates University, Al Ain, United Arab Emirates

  17:10-17:30

Speech Opportunity Available
Abstract and Biography: Submit Here

 

Session 421: Immunotherapy

Day 1: Afternoon, July. 12, 2023

Chair

Dr. Barbara Metzler, Head of Biology, Topas Therapeutics GmbH, Germany

 Co-Chair   Dr. Erminia Massarelli, Associate Professor, City of Hope, USA

Time

 

13:30-13:35

Chair's Introduction

13:35-14:00

Keynote Speech

Title: NKTR-255: A Potent NK and CD8 Memory T cell Mobilizer

Dr. Loui Madakamutil, VP, Head of Discovery, Nektar Therapeutics, USA

14:00-14:25

Title: Aviscumine-Another Immunotherapeutic Principle for The Treatment of Cancer

Dr. Hans Lentzen, VP Strategy and Innovation, LioniX International BV, the Netherlands

14:25-14:50

Title: The Use of Liver-targeting Nanoparticles to Induce Antigen-specific Immune Regulation

Dr. Barbara Metzler, Head of Biology, Topas Therapeutics GmbH, Germany

14:50-15:15

Speech Opportunity Available
Abstract and Biography: Submit Here

15:15-15:30

Coffee Break

15:30-15:55

Title: Bispecific T-Cell Engagers: Overview of Amgen‘s BiTE® Pipeline

Dr. Benno Rattel, Executive Director, Nonclinical Development, Amgen Research, Germany

15:55-16:20

Title: Novel Approach with Immunotherapy Combinations in Head and Neck and Non-small Cell Lung Cancers

Dr. Erminia Massarelli, Associate Professor, City of Hope, USA

16:20-16:45

Title: The Deep Impact of Translational Sciences in CAR T Cell Therapy Advancement

Dr. Jan Joseph (Jos) Melenhorst, Professor of Pathology & Laboratory Medicine; Director, Parker Institute for Cancer Immunotherapy Biomarker Program, University of Pennsylvania, USA

16:45-17:10

Title: Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms

Dr. Li Zhang, Professor and Senior Scientist, Toronto General Hospital Research Institute, University Health Network, University of Toronto, Canada

  

 

 



© 2003-2023 All rights reserved by BIT Congress
Contact Us:Tel:0086-411-84799609, Email:Irene@iddst.com